Trial Profile
A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; Epirubicin
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions
- 28 Mar 2018 Status changed from active, no longer recruiting to completed.
- 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 23 Aug 2012 Status changed from not yet recruiting to recruiting as reported by M.D. Anderson Cancer Center.